AR and prostate carcinoma: Liang and coworkers (Chuu et al.2011b) used variants of LNCaP prostate cancer cell lines todemonstrate that antiandrogen-resistant LNCaP cell lines with an AR-rich phenotype have a G1cell cycle blockade in the presence of androgens by regulating cMyc, Skp2 andp27kip via the AR.